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ABSTRACT 
Objective: To define the impact that the human immunodefi- 
ciency virus type 1 (HIV-l) epidemic has had on the burden and 
outcome of bacterial meningitis in an area with a high preva- 
lence of pediatric HIV-l infection. 
Methods: Children less than 12 years of age with proven or sus- 
pected bacterial meningitis were enrolled in this study between 
March 1997 and February 1999, and their hospital records 
were retrospectively reviewed for clinical data. 
Results: Sixty-two (42.2%) of the 147 children tested for HIV-l 
infection were infected. Streptococcus pneumoniae (Pnc) 
exceeded Haemophilus influenzae type b (Hib) as the most impor- 
tant cause of meningitis in HIV-l-infected (74.2% vs. 12.9%, 
respectively) compared with uninfected children (29.4% vs. 42.3%, 
respectively, P < 1 O-5). The estimated relative risk of Pnc menin- 
gitis was greater in HIV-I-infected than in uninfected children 
under 2 years of age (relative risk [RR] = 40.4; 95% confidence 
intervals [Cl] = 17.7-92.2). Overall, HIV-l -infected children had a 
higher rate of mortality than uninfected children (30.6% vs. 11.8%, 
respectively, P = O.Ol), and in particular, HIV-I -infected children 
with Pnc meningitis (60.8% vs. 36.0%, respectively, P = 0.04) 
had a poorer outcome. 
Conclusions: Streptococcus pneumoniae has exceeded Hib as 
the most important pathogen causing bacterial meningitis in 
HIV-1 -infected compared with uninfected children. Effective vac- 
cination against Hib and Pnc should be evaluated to reduce the 
overall burden of bacterial meningitis in HIV-I -infected children, 
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Children infected with human immunodeficiency virus 
type 1 (HIV-l) are recognized to be at increased risk of 
developing bacterial infections.‘** Despite detailed 
descriptions of the impact that HIV-l has had on bacte- 
rial pneumonia and invasive Streptococcuspneumoniae 
(Pnc) disease, the epidemiology of bacterial meningitis in 
children in areas where the prevalence of HIV-1 infec- 
tion is high remains ill defined.3-5 Based on necropsy 
results of all childhood deaths, HIV-l-infected and unin- 
fected African children under 15 months of age had a 
similar prevalence of bacterial meningitis (19% and 3 l%, 
respectively).5 The estimated incidence of pneumococcal 
meningitis is 40-fold increased in HIV-l-infected com- 
pared with uninfected children under 24 months of age.’ 
Vaccination with Haemophilus influenzae type b (Hib) 
conjugate vaccines has been highly successful in reduc- 
ing the burden of Hib meningitis and is responsible for 
a change in the epidemiology of bacterial meningitis in 
those developed countries where it has been instituted 
as part of routine childhood immunization; however, its 
availability in developing countries remains an issue.’ 
South Africa is the only country in subSaharan Africa 
that has funded Hib conjugate vaccination as part of its 
expanded program of immunization.’ The same coun- 
tries in subSaharan Africa most affected by the pediatric 
HIV-1 epidemic may have a great burden of Hib disease.7-9 
In an effort to define the impact that HIV-l has had on 
the epidemiology of meningitis in children and compare 
the outcome of bacterial meningitis in HIV-l-infected and 
uninfected children, all children with confirmed or sus- 
pected bacterial meningitis between March 1997 and 
February 1999 were enrolled into this study. 
MATERIALS AND METHODS 
Study Site and Population 
The study was performed at Chris Hani-Baragwanath 
Hospital in Soweto, South Africa, a secondary tertiary- 
level care institution with 450 beds for children. 
Haemophilus injluenzae type b conjugate vaccination 
was introduced into the expanded program of childhood 
immunization only in July 1999; however, children who 
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were participating in a trial evaluating a pneumococcal 
conjugate vaccine that started in March 1998 received 
Hib conjugate vaccine. This report excludes all children 
who were participating in the above-mentioned study 
and, therefore, is based on a cohort of children who were 
not vaccinated with either Hib or Pnc conjugate vaccines. 
The infant mortality rates in the community were esti- 
mated to be 32.5/1000 among HIV-uninfected children 
and 350/1000 among HIV-l-infected children. It is esti- 
mated that 57% of HIV-l-infected children die before the 
age of 2 years.“,1o Most HIV-l-infected children reside in 
individual homes and neither anti-retroviral or 
immunoglobulin therapy is available to these children. 
Children were identified as having meningitis based 
upon daily surveillance of all children admitted during 
the study period and with monitoring for cases of bac- 
terial meningitis at the level of the laboratory. Children 
under 12 years of age fulfiiling the defined criteria for 
bacterial meningitis were included. These included any 
child with at least one of the following criteria: (1) a pos- 
itive culture or Gram stain of any pathogenic bacteria in 
the cerebrospinal fluid (CSF); (2) a CSF neutrophil count 
of more than 5 cells/mm3 with signs of meningitis and at 
least one of the following: (a) a reactive latex antigen test 
for any of the following: Streptococcus pneumoniae 
(Pnc), Haemophilus in.uenzae type b (Hib), Neisseria 
meningitidis (Mnc), or Streptococcus agalactiae (GBS); 
or (b) a positive blood culture for any pathogenic organ- 
ism; and (3) a CSF white cell count of more than loo/mm3 
with more than 70% neutrophils. Excluded were children 
in whom a clinical or laboratory diagnosis of viral, tuber- 
culous, or cryptococcal meningitis was made. Meningitis 
occurring in children resident in the neonatal wards since 
birth was also excluded from this study. Demographic 
and clinical information were collected at the time of 
recruitment. At the end of the study period, the hospital 
records of children were reviewed to defme the clinical 
presentation and course of their illness. 
Blood and Cerebrospinal Fluid Culture Techniques 
Blood and CSF culture techniques were performed as per 
routine laboratory procedure using the BacT/Alert@ 
(Organon Teknika, Durham, NC) microbial detection sys- 
tem and by direct plating of CSF using 5% blood agar 
and chocolate agar media. 
Antimicrobial Susceptibility Testing 
The National Committee for Clinical Laboratory Standards 
(NCCIS) guidelines and breakpoints were used for report- 
ing antimicrobial susceptibility.11J2 In addition to the use 
of the disk-diffusion method, minimum inhibitory con- 
centrations (MIC) for S. pneumoniae isolates expressing 
reduced susceptibility on disk diffusion test were per- 
formed using the broth microdilution method with cation 
adjusted Mueller-Hinton broth. 
Streptococcus pneumondae and Haemophilus 
inftuenzae %e b Serotyping 
Serogrouping of S. pneumoniae isolates was performed 
using the quellung method with specific pneumococcal 
antisera (Statens Seruminstitut, Copenhagen, Denmark). 
Routine methods were used for culture and identifi- 
cation of H. influenzae type b from blood and CSF sam- 
ples. The capsular type of H. injluenzae was identified 
using H. injluenzae agglutinating sera (Murex Biotech 
Limited, Dartford, UK). Beta-lactamase production was 
detected by a chromogenic assay 
Cerebrospinal Fluid Latex Antigen Detection 
The Wellcogen@ Bacterial Antigen Kit (Murex, Wiesbaden, 
Germany) was used to perform latex tests on CSF samples. 
Human Immunodefkiency Virus Testing 
Human immunodeficiency virus type 1 was diagnosed 
based on two reactive third generation enzyme-linked 
immunosorbent assay (ELISA) tests (Axsym@ System, 
HIV1/2, Abbott Diagnostics, Wiesbaden-Delkenheim, Ger- 
many, and Wellcozyme HIV 1+2 EIA test, Murex Diagnos- 
tics Ltd., Dartford, UK). Children under 15 months of age 
with reactive HIV ELISA tests and who had less than three 
signs of the Centers for Disease Control and Prevention 
(CDC) HIV clinical category A were confirmed using an 
HIV DNA polymemse chain reaction (PCR) (Amplicor HIV- 
1 test, version 1 .O, Roche Diagnostics, Nutley, NJ). The pre- 
sent episode of bacterial meningitis was not included in 
the CDC HIV clinical categorization of the child. 
Computed Tomography of the Brain 
Computed tomography (CT) of the brain was performed at 
the discretion of the attending physician if clinically indicated. 
Definitions 
Neurologic sequelae were categorized as evidence of any 
of the following: motor function impairment, as suggested 
by quad- or hemiparesis or spastic&y; hydrocephalus; hear- 
ing impairment; and seizure disorders requiring mainte- 
nance therapy at the time of discharge. Motor abnormalities 
were graded as being mild-moderate or severe, based on 
the functional status of the child. Mental impairment was 
not evaluated. Data regarding neurologic outcome were 
based on the findings at the time of discharge. 
Children were classified as being malnourished if 
they fulfilled the Wellcome criteria for kwashiorkor or 
marasmus.r3 
Statistics 
Data were analyzed using Epi Info version 6.04~ (Cen- 
ters for Disease Control and Prevention, Atlanta, GA). 
Analysis of variance and the Kruskal-Wallis H test for two 
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Age-Group (mo) 
<l.O 
1.1-6.0 
6.1-12.0 
12.1-24.0 
24.1-60.0 
>60.0 
Total 
Medianage 
25th-75th centile 
S. pneumoniae H. influenzae Type b N. meningitidis S. agalactiae 
H/V+ (%) H/V- (%) HIV+ (%) HIV- (%) HIV+ (%) H/V- (%j H/V+ (%) H/V- (%) 
3 (6.5) 2 (8.0) - 1 (2.8) - I (33.3) 8 (100) 
10(21.7) 11 (44.0) 3 (37.3) 10(27.8) 1 (25.0) i(27.3) 2 (66.7) - 
15 (32.6) 3 (12.0) 1 (12.5) 19 (52.8) - - - 
6 (13.1) 3(12.0) 2 (25.0) 5 (13.9) 1 (9.1) - 
6 (13.1) 2 (8.0) 1 (12.5) 1 (2.8) 1 (25.0) 3 (27.3) - - 
6 (13.1) 4 (16.0) 1 (12.5) - 2 (50.0) 4 (36.3) - - 
46 (100) 25 (100) 8 (100) 36 (100) 4 (100) 11 (100) 4 (100) 8 (100) 
8.6 5.0 15.2 8.5 66.2 32.9 1.1 0.6 
5.4-24.4 2.6-16.2 5.0-33.0 5.7-11.5 31.3-84.5 4.9-75.8 0.1-1.5 0.2-0.6 
Table 1. Age-Group Distribution of Human lmmunodeficiency Virus Type 1 -infected (HIV+) 
and Uninfected (HIV-) Children with Bacterial Meningitis 
groups was used for parametric and non-parametric data, 
respectively. The Mantel-Haenszel chi-squared test was 
used when comparing categoric data, and the 2-tailed 
Fisher’s exact test was used when an expected cell value 
was less than 5. 
The estimated incidence rates for organism-specific 
meningitis in children under 1 and 2 years of age was 
based on children admitted during the frost half of the 
study period only (prior to the introduction of Hib or 
Pnc conjugate vaccines into the community). The esti- 
mated population denominator for HIV-infected and unin- 
fected children was based on a birth cohort of 22,000 
children and a prevalence of HIV among women attend- 
ing antenatal care in 1997 being 17% with a vertical trans 
mission rate of 26%.8,14 Hence, it was estimated that 
approximately 4.45% of all children born were HIV-l 
infected. Adjustments were made for the described mor- 
tality in HIVl-infected and uninfected children under 2 
years of age when calculating the estimated relative inci- 
dence risks. An o-value of less than 0.05 was considered 
significant. 
Ethics 
The study was approved by the Ethics Committee for 
Research on Human Subjects of the University of the Wit- 
watersrand. Informed consent for inclusion into the study 
was obtained from the parent or guardian of each child. 
RESULTS 
Demographics 
Results of HIV-l tests were available for 147 of 161 cases 
identified, of whom 62 of 147 (42.2%) were HIV-l- 
infected. None of the 14 children of unknown or inde- 
terminate HIV-l status, whose median age (25th-75th 
centile) was 16.9 months (range, 15.2-54.6 mo), had clin- 
ical features in keeping with the CDC HIV categories A 
to C. The spectrum of organisms isolated from these chil- 
dren was similar to that of the HIV-l-uninfected children 
(P = 0.28) and differed from that of the HIV-l-infected 
children (P < 0.0001). The isolates among these children 
included one case of Pnc (age, 119 mo), six cases of Hib 
(ages, 4.7,8.4,16.1,17.1,34.2, and 121.5 mo),four cases 
of Mnc (ages, 16.7, 16.8, 49.9, and 54.6 mo), one child 
with GBS (age, 0.2 mo), and two children with no isolate 
(ages, 15.2 and 95.2 mo). These 14 children were 
excluded from further analysis. 
The median ages of the remaining 147 children 
(25th-75th centile) were 8.4 months (range, 5.2-31.2 
mo) and 8.2 months (range, 3.1-16.8 mo) (P = 0.21),and 
males accounted for 29 of 62 (46.8%) and 48 of 85 
(56.5%, P = 0.24) of HIV-l-infected and uninfected chil- 
dren, respectively. There were no differences in the 
median ages between HIV-l-infected and uninfected chil- 
dren for a particular infecting organism; however, chil- 
dren with Mnc were older and those with GBS younger 
compared with children with Pnc or Hib meningitis (P 
< 0.05) (Table 1). 
Clinical and Laboratory Features 
Clinical signs and symptoms suggestive of meningitis did 
not differ between groups except that impaired level of 
consciousness was more common in HIV-l-infected chil- 
dren, particularly for children with Pnc meningitis (19/35 
[54.3%3 vs. 5/20 [25%] in HIV-l-infected and uninfected 
children, respectively, P = 0.03) (Table 2). There were no 
organism-specific differences in the level of conscious- 
ness in HIV-l-infected or uninfected children at the time 
of admission. Children infected with HIV-l also had more 
concurrent pneumonia, local suppurative conditions 
involving the middle ears, mastoid, or sinuses, and severe 
malnutrition than uninfected children (see Table 2). The 
spectrum of bacteria was similar between the two 
groups, but the specific distribution by bacteria differed 
between HIV-l-infected and uninfected children (P < 
10m5). Whereas Hib was the most common pathogen iso- 
lated in HIV-l-uninfected children (36/85 [42.4%]), Pnc 
was the most prevalent organism responsible for menin- 
gitis in HIV-l-infected children (46/62 [74.2%]) (Figure 1). 
Although the relative risk for developing meningitis was 
greater in HIV-l-infected than in uninfected children less 
than 1 or 2 years of age for all three pathogens, only the 
difference for Pnc was statistically significant (Table 3). 
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Table 2. Signs and Symptoms in Human lmmunodeficiency Virus Type l-Infected (HIV+) 
and Uninfected (HIV-) Children with Bacterial Meningitis 
Clinical feature 
On antibiotics at admission 
History of fever 
History of seizures 
Median duration of symptoms (25th-75th) (d) 
Seizures in hospital 
History of irritability 
Stupor or coma on admission 
Concurrent pneumonia 
Suppurative otitis media, mastoiditis, sinusitis 
Malnourished* 
H/V+ HIV- 
n = 62 (700%) n = 85 (100%) 
21 (33.9) 20 (23.5) 
53 (85.5) 75 (88.2) 
18 (29.0) 24 (28.2) 
2 (l-3) 2 (i-3) 
26 (41.2) 27 (31.8) 
33 (53.2) 42 (49.4) 
18149 (36.7) 13/72 (18.0) 
21 (33.8) 9 (10.6) 
5 (8.0) 1 (1.0) 
11 (17.8) 3 (3.5) 
P-Value 
0.16 
0.62 
0.91 
0.38 
0.43 
0.64 
0.02 
0.0005 
0.08 
0.003 
*Kwashiorkor or marasmus based on the Wellcome classification. 
Positive Gram stain or culture from CSF was more 
common in HIV-l-infected children than in uninfected 
children, and HIV-l-infected children also tended to have 
lower lymphocyte counts and a higher protein content 
in the CSF (Table 4). Previous antibiotic therapy did not 
influence the mean CSF neutrophil (P > 0.6) or lym- 
phocyte counts (P > 0.12) in HIV-l-infected children or 
in uninfected children. Furthermore, the mean white cell 
count, hemoglobin concentration, and platelet counts 
were lower in HIV-l-infected children than in uninfected 
children (see Table 4). 
Antibiotics used included cefotaxime (150-200 
mg/k&d) or ceftriaxone (100 mg&$d) only in 118 (83%) 
of 142 of the children, cefotaxime or ceftriaxone with 
vancomycin (40 mg/kg/d) in 9 (6.3%) of 142 children, 
penicillin in 12 (8.5%) of 142 children, and other anti- 
biotics in 3 (2.1%) of 142 children. Data regarding anti- 
biotic usage was unavailable in five children. Eight of the 
nine children in whom cefotaxime or ceftriaxone with 
vancomycin was used cultured Pnc, four of which were 
sensitive to penicillin, three expressed intermediate sus- 
ceptibility, and one was resistant; these included two iso- 
lates with intermediate susceptibility to cefotaxime. 
Outcome 
The overall spectrum of neurologic sequelae observed 
in HIV-l-infected and uninfected children is shown in 
Table 5. Overall, HIV-l-infected children had a higher mor- 
tality than uninfected children (lW62 [30.6%] and 1 l/85 
[ll.S%], respectively) (RR = 2.24; 95% CI = 1.14-4.41; 
Figure 1. Bacterial isolates in human immunodeficiency virus type 
1 -infected (clear bars) and uninfected (black bars) children with bac- 
terial meningitis. Percentages refer to proportional representation of 
each pathogen within the specific HIV-1 group. 
P = 0.01). Severe malnutrition was a significant risk factor 
for mortality in HIV-l-infected children (7/11 [63.6%] vs. 
11/51 [21.6%1) (RR = 2.95; 95% CI = 1.48-5.87; 
P = 0.009). There was no difference in mortality among 
HIV-l-infected children based on CDC clinical catego- 
rization of HIV-1 infection. Eight (22.9%) of 35 children cat- 
egorized as in clinical stage B died compared with 10 
(37.0%) of 27 children categorized as in stage C (P = 0.22). 
Abnormal findings in those children with clinical 
indications for CT of the brain were detected in 14 
(82.3%) of 17 HIV-l-infected and 20 (83.3%) of 24 unin- 
fected children. The spectrum of abnormalities on CT 
did not differ by HIV-l status. Of the 41 children in whom 
CT was performed, 41.5% had evidence of cerebral infarc- 
tion, 31.7% had hydrocephalus, 24.4% had cerebral atro- 
phy, 17.0% had cerebral edema, 14.6% had subdural 
effusions, and there was one case of a cerebral abscess 
in a child with HIV-1 infection and one case of subdural 
empyema in an uninfected child. 
In children with Pnc meningitis, poor outcome, 
defined as neurologic sequelae or death, was more com- 
mon in HIV-l-infected children than in uninfected children 
(Table 6). There was no difference in outcome in HIV-l- 
infected (P = 0.83) or uninfected children (F = 0.32) with 
Pnc penicillin-susceptible isolates compared with Pnc peni- 
cillin-resistant isolates treated with cefotaxime or ceftri- 
axone. The adverse outcomes among the children treated 
with cefotaxime or ceftriaxone with vancomycin included 
one death in a child with a Pnc isolate that had inter- 
mediate susceptibility to penicillin and one episode each 
of mild-moderate and severe neurologic sequelae among 
the four children with penicillin-susceptible Pnc isolates. 
In HIV-l-infected and uninfected children with Hib 
meningitis, neurologic sequelae were observed in 5 (71.4%) 
of 7 and 10 (33.3%) of 30 (RR = 2.14; 95% CI = 1.08-4.27; 
P = 0.09) of the survivors, and the mortality rates were 
12.5% (l/8) and 16.7% (6/36) (P = 1 .O>, respectively. Of 
children with Hib meningitis, beta-lactamase-producing iso- 
lates were found in 1 (12.5%) of 8 HIV-l infected children 
and 8 (22.2%) of 36 uninfected children (P = 0.54). 
The proportion of children with neurologic sequelae 
did not differ between HIV-l-infected and uninfected chil- 
dren with meningitis attributable to Mnc (O/4 and 2/11 
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Table 3. Estimated Relative Risk per 100,000 of Bacterial Meningitis in Human lmmunodeficiency 
Virus Type 1 -infected (HIV+) and Uninfected (HIV-) Children 
Organism Overall H/V+ HIV- Relative Risk* (95% Cl) P-Value 
Streptococcus pneumoniae 
Ily 102 1541+ 39 39.50 (16.6-94.1) <10-s 
<2y 56 885$ 22 40.40 (17.7-92.2) 40-S 
Haemophilus influenzae type b 
<ly 75 110+ 63 1.74 (0.23-13.2) 0.45 
<2y 47 118+ 37 3.20 (0.74-14.2) 0.14 
Neisseria meningitidis 
<ly 14 110 10 11.30 (1.03-124.5) 0.12 
52y 9 59 7 8.00 (0.84-77.6) 0.14 
*Refers to comparisons between HIV-1 -infected and uninfected children. Comparisons of estimated relative incidence rates between S. pneumoniae and H. 
hfluenzae type b meningitis: tP = 0.0007 (RR = 14.0; 95% Cl = 1.84-106.25); 2P = 0.001 (RR = 7.50; 95% Cl = 1.72-32.25). There were no significant differences in 
organism-specific estimated incrdence rates in HIV-1 -uninfected children between H. influenzae type b and S. pneumoniae meningitis. 
[lS.Z%];P = 1.0) or GBS (O/4 and 2/S [25.O%];P = 0.51). 
There were no deaths observed in children with GBS or 
Mnc meningitis. 
DISCUSSION 
Approximately 75% of children infected by HIV-l are liv- 
ing in sub-Saharan Africa, with South Africa being one of 
the most affected of countries8a9 Coupled with this 
increased burden of HIV-l infection, African children are 
at risk of serious invasive bacterial infection. The impact 
that the HIV-l epidemic has had on invasive bacterial 
meningitis, particularly in sub-Saharan Africa remains 
poorly defined. 4,5 Although data from adult studies sug- 
gest that HIV-l may be associated with a slightly more 
favorable prognosis in adults with Pnc meningitis,15 the 
effect that HIV-l has had on the outcome of bacterial 
meningitis in children is unknown. The present study 
suggests that HIV-l-infected children with bacterial 
meningitis, particularly that attributable to Pnc, have a 
poorer outcome than uninfected children. The limitations 
of this study, however, include that data regarding neu- 
rologic outcome were based on review of hospital 
records, in addition to which there was no long-term fol- 
low-up for hearing assessment, resolution of motor impair- 
ment, or mental impairment as has been observed in 
other studies. l6 Furthermore, data regarding the baseline 
neurologic status were unavailable. Since HIV-l is recog- 
nized to infect the central nervous system (CNS) and 
result in neurologic impairment, this confounding vari- 
able may have had an important impact regarding the 
neurologic assessment of HIV-l-infected children.‘7~18 
Overall, the morbidity and mortality observed in HIV-l- 
infected and uninfected children in this study was greater 
than that observed in children from developed countries 
(morbidity of 17.5-26.1% and mortality of 4.8-&l%) but 
comparable with that from Sudan (22-33% morbidity and 
25% mortality), although in the latter study, morbidity was 
based on long-term follow-up of those children.‘Q” The 
differences in both morbidity and mortality may also be 
related to differences in the etiology of bacterial menin- 
gitis in different studies. l9 In the present study, Mnc, 
which is usually associated with a favorable prognosis, 
was not an important pathogen, whereas Pnc, which is 
usually associated with a worse prognosis was a more 
dominant cause of meningitis, particularly among HIV-l- 
infected children. l9 Furthermore, the high proportion of 
children receiving antibiotics at the time of admission 
suggests delay in the diagnosis of meningitis. 
Despite the cited limitations, the results demonstrate 
that the HIV-l epidemic has had a major impact on alter- 
ing the epidemiology of bacterial meningitis in an area 
where the prevalence of HIV-l among infants was esti- 
mated to be at least 4.45% and during an era when Hib 
conjugate vaccine was not routinely used in the com- 
Table 4. Laboratory Data of Human lmmunodeficiency Virus Type 1 -Infected (HIV+) and Uninfected (HIV-) Children with Bacterial Meningitis 
Analysis 
CSF analysis 
Culture positive 
Latex positive 
Gram stain positive 
Median neutrophil count (cells/mm3)* 
Median lymphocyte count (cells/mm3)* 
Mean protein (SD) (g/L) 
Blood analysis 
Blood culture positive 
Whole blood count: (SD) (cells/L)+ 
Hemoglobin (SD) g/dL 
Platelet count x 1 Og (SD) (cells/L) 
C-reactive protein (SD) (g/L) 
*25th-75th, ‘WBC x 1 Og. 
H/V+ HIV- 
n = 62 (100%) n = 85 (100%) 
60 (96.8) 73 (85.9) 
18128 (64.3) 28/43 (65.1) 
60 (96.8) 67184 (79.8) 
263 (80-515) 325 (125-913) 
35 (8.5-108.5) 55 (23-l 89) 
3.9 (3.6) 2.9 (2.5) 
40 (64.5) 49 (57.6) 
13.1 (8.0) 17.0 (10.2) 
8.83 (2.0) 10.0 (2.3) 
259.5 (164.3) 354.1 (207.3) 
173.9 (130.9) 153.9 (93.3) 
P-Value 
0.02 
0.94 
0.002 
0.12 
0.09 
0.04 
0.40 
0.03 
0.0006 
0.004 
0.27 
OR; 95% CI 
4.93; 1.03-46.66 
7.61; 1.59-49.8 
1.12; 0.86-1.45 
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Table 5. Neurologic Outcome Observed in Surviving Human lmmunodeficiency Virus 
Type l-Infected (HIV+) and Uninfected (HIV-) Children with Bacterial Meningitis 
Neurologic Abnormality 
H/V+ HIV- 
n = 44 (100%) n = 74 (100%) RR (95% Cl) P-Value 
Neurologic sequelae* 16 (36.4)+ 19 (25.7)* 1.42 (0.82-2.46) 0.22 
Sensorineural hearing impairment” 5/l 5 (33.3) 4/23 (17.4) 1.92 (0.61-6.01) 0.43 
Quadriplegia 5 (11.4) 5 (6.8) 1.68 (0.52-5.48) 0.49 
Hemiplegia 7 (15.9) 9 (12.2) 1.31 (0.52-3.26) 0.57 
Unresolved seizures1 6 (13.6) 6 (8.1) 1.68 (0.58489) 0.35 
Hydrocephalus’ 3 (6.8) 10 (13.5) 0.50 (0.15-l ,731 0.37 
*Motor function or sensorineural hearing impairment, hydrocephalus, or seizures requiring maintenance medication at discharge. +Eight children with mild-moderate 
and eight with severe neurologic sequelae. Seven children with mild-moderate and 12 children with severe neurologic sequelae. §Excludes four HIV-1 -infected and 
eight uninfected children in whom assessment could not be performed owing to presence of middle ear effusion. IChildren with seizures requiring marntenance 
therapy at discharge. ‘Based on computed tomography of the brain obtained at the discretion of the attending physician. 
munity. Streptococcus pneumoniae has exceeded Hib as 
the most important cause of meningitis in children from 
this area. This may be a consequence of a heightened 
predisposition of HIV-l-infected children to Pnc, more so 
than to Hib or Mnc, as suggested by the estimated rela- 
tive incidence rates for each of these bacteria. Although 
exclusion of the children whose HIV-l status was 
unknown may have influenced the estimated incidence 
rates, particularly for Hib and Mnc, since these children 
did not have stigmata of AIDS, this would probably have 
resulted in an underestimation of the incidence rates for 
HIV-l-uninfected children. 
The greater organism-specific risk for developing Pnc 
meningitis in HIV-l-infected children may be attributable 
to differences in the immune response required to eradi- 
cate Pnc, Hib, and Mnc. Whereas humoral immunity, includ- 
ing antibody- and complement-mediated direct bactericidal 
activity may be sufficient for eradicating invasive Hib and 
Mnc, the killing of Pnc is dependent upon antibody- and 
complement-mediated opsonization activity, coupled with 
killing by an intact phagocytic system.7~*0*21 In HIV-l- 
infected children, whereas impairment of all arms of the 
immune system has been demonstrated, it is impairment 
of T lymphocyte-mediated immunity that is affected the 
earliest and the most severely; in addition to this, impaired 
neutrophil activity exists in HIV-l-infected children2* The 
increased predisposition of HIV-l-infected children to 
develop mastoid&is, suppurative otitis media, and sinusitis 
may further have impacted the epidemiology of meningi- 
tis in these children.’ The trend toward a greater propor- 
tion of HIV-l-infected children having these concurrent ill- 
nesses may suggest that contiguous spread of bacteria to 
the meningial space is a more common mode of disease 
in the pathogenesis of bacterial meningitis in HIV-l-infected 
children than in uninfected children. 
The direct effects of HIV-l itself may largely explain 
the differences in the laboratory features observed in 
HIV-l-infected and uninfected children. Suppression of 
the bone marrow may have contributed to the lower 
white cell count, hemoglobin concentration, and platelet 
count observed in HIV-l-infected children.” Furthermore, 
the increased protein concentration in the CSF may have 
been attributable to direct underlying CNS involvement 
by HIV-l; however, it also is a marker of more severe 
blood-brain barrier impairment, which could contribute 
to increased vasogenic edema and a more unfavorable 
outcome, as was observed in HIV-l-infected children.23,24 
The greater proportion of HIV-l-infected children than 
uninfected children in whom CSF was positive for culture 
and Gram stain may have been attributable to an impaired 
immune response following bacterial invasion into the 
CSF space and has been associated with a higher con- 
centration of bacteria and more severe disease.25,26 
Despite the increased burden of Pnc meningitis in 
HIV-l-infected children, the antibiotic susceptibility of 
involved serogroups did not differ compared with that 
observed for HIV-l-infected chiklren and uninfected children 
with Pnc bacteremic pneumonia.3 A similar combination of 
serogroups with similar antibiotic susceptibility profiles is 
responsible for causing Pnc meningitis in HIV-l-infected 
Table 6. Streptococcus pneumoniae Meningitis in Human lmmunodeficiency Virus Type 1 -Infected (HIV+) and Uninfected (HIV-) Children 
H/V+ HIV- 
n = 46 (700%) n = 25 (100%) RR (95%CI) P-Value 
Outcome 
Cure 18 (39.1) 16 (64.0) 0.61 (0.38-0.97) 0.04 
Neurologic sequelae 11 (23.9) 4 (16.0) 1.49 (0.53-4.21) 0.43 
Deaths 17 (36.9) 5 (20.0) 1.85 (0.77-4.41) 0.14 
Any adverse event 28 (60.8) 9 (36.0) 1.69 (0.95-2.99) 0.04 
Penicillin susceptibility 
Intermediate susceptibility 13 (28.3) 9 (36.0) 0.50 
Resistant 2 (4.3) 0 0.53 
Cefotaxime resistance 1 (2.2) 1 (4.0) 1 .oo 
Nine-valent conjugate vaccine serogroups* 33/40 (82.5) 18/24 (75.0) 0.53 
*includes serotypes 1, 4, 5, 65, 9V, 14, 1 BC, 19F, 23F: 1 l/64 (17.2%) serogroup 6, of which 50% (3/6) were serotype 6B, and1 6164 (25%) serogroup 19, of which 
54.5% (6/l 1) were serotype 19F. 
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children and in uninfected children? Resistance to cefotaxime 
of Pnc isolates from CSF remains low in HIV-l-infected and 
uninfected children in this country Therefore, the present 
empirical treatment of meningitis using cefotaxime or cef- 
triaxone remains adequate in this area for the management 
of bacterial meningitis. 
Although Hib conjugate vaccine may be successful in 
reducing the burden of meningitis in children not 
infected with HIV-l, its impact in HIV-l-infected children 
is less effective, considering that Pnc is the dominant 
cause of meningitis in these children. The impact of either 
Hib or Pnc conjugate vaccines on meningitis in HIV-l- 
infected children is currently unknown. 
CONCLUSION 
The HIV-1 epidemic has resulted in a change in the epi- 
demiology of bacterial meningitis in children with a high 
prevalence of HIV-1 infection, such that Pnc meningitis 
has emerged as being more common than Hib meningi- 
tis. The poorer outcome observed in HIV-l-infected chil- 
dren may largely be explained by the increase in Pnc 
disease and poorer nutritional status of these children. 
Although, prevention of mother-to-child transmission of 
HIV-1 would probably be the most effective strategy to 
reduce the burden of bacterial meningitis in an area with 
high HIV-1 prevalence, effective vaccination against Hib 
and Pnc should be evaluated to reduce the overall bur- 
den of bacterial meningitis in HIV-l-infected children. 
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